De Leo V, la Marca A, Morgante G
Institute of Obstetrics and Gynecology, Siena University, Italy.
Gynecol Obstet Invest. 1999;47(4):258-62. doi: 10.1159/000010118.
The aim of this study was to evaluate the effects of danazol in reducing the volume of fibromyomas and in the treatment of associated symptoms. Twenty women (34-42 years) with uterine fibromyomas were treated with 400 mg/day of danazol for 4-month periods. The women underwent ultrasound examination to determine their uterine volume at enrollment in the follicular phase and after 2 and 4 months. The examination was repeated by the same sonographer 3 and 6 months after the end of therapy. Blood samples were taken on the same days for LH, FSH, estradiol and progesterone assays. After therapy, fibromyoma volume decreased significantly (p<0.01) by an average of 23.6+/-5%. All patients experienced partial or complete relief of symptoms while using danazol. Three and six months after the end of treatment the fibromyoma volume had only increased slightly with respect to the volume at the end of therapy, but was still lower than the starting volume. The present study shows the efficacy of danazol at a dose of 400 mg/day for 4 months in reducing the volume of fibromyomas and associated symptoms. The mechanism by which danazol reduces the volume of fibromyomas may be due to reduced estrogen concentrations and to its antiprogesterone effects on uterine myomas.
本研究的目的是评估达那唑在减小子宫肌瘤体积及治疗相关症状方面的效果。二十名患有子宫肌瘤的女性（年龄在34至42岁之间）接受了为期4个月、每日400毫克达那唑的治疗。这些女性在卵泡期入组时以及治疗2个月和4个月后接受超声检查以确定子宫体积。治疗结束后3个月和6个月，由同一位超声检查医师重复进行检查。在相同日期采集血样以检测促黄体生成素（LH）、促卵泡生成素（FSH）、雌二醇和孕酮。治疗后，子宫肌瘤体积显著减小（p<0.01），平均减小了23.6±5%。所有患者在使用达那唑期间症状都得到了部分或完全缓解。治疗结束后3个月和6个月，子宫肌瘤体积相对于治疗结束时仅有轻微增加，但仍低于起始体积。本研究表明，每日400毫克、为期4个月的达那唑剂量在减小子宫肌瘤体积及相关症状方面具有疗效。达那唑减小子宫肌瘤体积的机制可能是由于雌激素浓度降低及其对子宫肌瘤的抗孕激素作用。
